Rare Nrg1 Fusion Market

DelveInsight’s ‘Rare NRG1 Fusion - Market Insights, Epidemiology, and Market Forecast—2030’ report delivers an in-depth understanding of the Rare NRG1 Fusion, historical and forecasted epidemiology as well as the Rare NRG1 Fusion market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom) Japan, and China


The Rare NRG1 Fusion market report provides current treatment practices, emerging drugs, Rare NRG1 Fusion market share of the individual therapies, current and forecasted Rare NRG1 Fusion market size from 2018 to 2030 segmented by eight major markets. The Report also covers the current Rare NRG1 Fusion treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
  • China

Study Period: 2018–2030

Rare NRG1 Fusion: Disease Understanding and Treatment Algorithm

Rare NRG1 Fusion Overview

NRG1 (Neuregulin 1) gene fusions are potentially actionable oncogenic drivers that are present in some solid tumors. NRG1 fusions result in ErbB-mediated pathway activation and present a rational therapeutic target. Oncogenic fusions of NRG1 may cause excess accumulation of the NRG1-fusion protein at the cell surface. This causes persistent activation of ErbB receptor tyrosine kinases that drive excess activity in the mTOR and MAPK pathways and promote tumorigenesis. The NRG1 gene encodes ligands for the ERBB2 (HER2)-ERBB3 heterodimeric receptor tyrosine kinase. Gene fusions of NRG1 such as CD74-NRG1 and SLC33A2-NRG1 have been found at low frequency in a wide range of carcinomas including lung, breast, colorectal, ovarian, and pancreatic cancers and with a wide range of fusion partners.


CD74-NRG1 fusion gene has been identified in a portion of invasive mucinous adenocarcinomas (IMA) of the lung. However, the function of the CD74-NRG1 fusion gene in adenocarcinoma pathogenesis and the mechanisms by which it may impart protumorigenic characteristics to cancer stem cells (CSC) is still unclear. A range of NRG1 fusion partners beyond CD74 has been identified, and they also vary among cancer types. In NSCLC, other fusion partners include the SDC4, SLC3A2, and ATP1B1 genes. In other malignancies, the genes SETD4, TSHZ2, and ZMYM2 (ovarian cancer); ADAM9 and COX10-AS1 genes (breast cancer); and CDH1 and VTCN1 genes (pancreatic cancer) are among known fusion partners of NRG1.


Rare NRG1 Fusion Diagnosis

Fusions involving the neuregulin-1 gene (NRG1) were first identified by transcriptome sequencing of lung adenocarcinomas, which revealed fusion of CD74 to NRG1. NRG1-fusion proteins and genes in solid tumors are detected primarily using immunohistochemistry and fluorescence in situ hybridization (FISH) techniques, DNA next-generation sequencing (NGS), and targeted gene fusion panels on RNA. The gold standard for the detection of NRG1 gene fusions is RNA sequencing in comparison with DNA sequencing. Although fluorescence in situ hybridization (FISH) can be used as a pre-screening method for its detection, only genetic sequencing will allow the identification of the gene fusion. RNA-sequencing is associated with higher sensitivity for genetic rearrangements and can increase the detection of NRG1 gene fusions compared with DNA-based methods, which often do not cover the large introns in NRG1.


Rare NRG1 Fusion Treatment

NRG1 gene fusions result in the activation of ErbB2-/ErbB3-mediated signaling pathways and may function as oncogenic drivers. NRG1 fusions have emerged as a potential therapeutic target across multiple tumor types, including NSCLC.


For NRG1 fusions, there are currently no approved targeted therapies. Standard therapy for advanced tumors harboring NRG1 fusions remains chemotherapy and/or immunotherapy or novel anti–PD-1 or anti–PD-L1 agents. The problem with utilizing these therapies is that response tends to be suboptimal for patients with NRG1 fusions. Several clinical reports have demonstrated that NRG1 fusions are a viable, actionable target in tumors, with responses seen on inhibition of ERBB family members.

Rare NRG1 Fusion Epidemiology

The Rare NRG1 Fusion epidemiology division provides insights about the historical and current Rare NRG1 Fusion patient pool and forecasted trends for every eight major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.


Key Findings

In the year 2020, the total incident case of Rare NRG1 Fusion was 12,934 cases in the 8MM which are expected to grow during the study period, i.e., 2018–2030.


The disease epidemiology covered in the report provides historical as well as forecasted Rare NRG1 Fusion epidemiology [segmented as Total Incident Cases of NRG1 Fusion, Total Stage-specific Cases of NRG1 Fusion, and Total Treated cases of NRG1 Fusion] in the 8MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), Japan, and China from 2018 to 2030.

Country Wise- Rare NRG1 Fusion Epidemiology

Estimates show that the highest cases of NRG1 Fusion in the 8MM were in China, followed by the United States, Japan, Germany, France, Italy, the United Kingdom, and Spain in 2020.

  • In the United States, the total number of incident cases of NRG1 Fusion was 2,253 cases in the year 2020 which are expected to grow during the study period, i.e., 2018–2030.
  • In the year 2020, the total incident cases of NRG1 Fusion were 2,527 cases in EU-5 which are expected to grow during the study period, i.e., 2018–2030.
  • In Japan, the total number of incident cases of NRG1 Fusion was 1,341 cases in the year 2020 which are expected to grow during the study period, i.e., 2018–2030.
  • In China, the total number of incident cases of NRG1 Fusion was 6,813 cases in the year 2020 which are expected to grow during the study period, i.e., 2018–2030.

Rare NRG1 Fusion Drug Chapters

The drug chapter segment of the Rare NRG1 Fusion report encloses the detailed analysis of Rare NRG1 Fusion late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Rare NRG1 Fusion clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.


Rare NRG1 Fusion Emerging Drugs


Tarloxotinib (Rain Therapeutics)

Tarloxotinib is Rain Therapeutics’ lead program in development as a treatment for patients with cancers driven by the ErbB/HER family of genes (including EGFR, HER2, HER3, and HER4). It is a tumor hypoxia-activated prodrug of a potent pan-ErbB (pan-HER) inhibitor. This unique mechanism of activation and delivery of active drug where it is needed (i.e. the site of the tumor) rather than where it is not wanted (i.e. healthy cells), provides patients a targeted strategy that has the potential to attack the tumor, without the debilitating side effects and dose-limitations of non-targeted therapies.


MM-121/Seribantumab (Elevation Oncology)

MM-121 (Seribantumab) is a fully human monoclonal antibody by Elevation Oncology. It is designed to stop the HER3 signaling that sustains an NRG1 fusion-positive tumor. Seribantumab binds to HER3 so that the NRG1 fusion protein that over-activates it, cannot bind to it. Seribantumab is being developed as a precise treatment path for patients whose tumor growth is driven by an NRG1 fusion. MM-121 is currently in the Phase II clinical development stage. It is now being studied in patients with solid tumors of any origin that test positive for an NRG1 fusion. US FDA granted seribantumab Fast Track designation and Orphan Drug Designation for development in patients with heregulin-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has progressed following immunotherapy


Zenocutuzumab/MCLA-128 (Merus)

Zenocutuzumab (MCLA-128) is an experimental medicine that is being developed by Merus. It is believed to work by blocking the action of the growth factor NRG1, a protein that can be overproduced due to NRG1 Fusions and prohibiting it from binding to HER3. HER3 is a protein that sits on the surface of cancer cells, which when it combines with a second surface protein HER2, sends signals to drive tumor growth and survival. NRG1 induces the combination of HER2 and HER3. Zenocutuzumab is a bispecific antibody, which means it can recognize two different proteins, specifically HER2 and HER3. It is designed to have a dock and block mechanism. Currently, Zenocutuzumab is in the Phase II clinical development stage for the treatment of NRG1 fusion Solid Tumors.


AV-203/CAN017 (CANbridge Pharmaceuticals/AVEO Oncology)

AV-203 (CAN017) is a clinical-stage ErbB3 (HER3) inhibitory antibody candidate designed by AVEO Oncology and is being developed in collaboration with CANbridge Pharmaceuticals. AV-203 inhibits both ligand-dependent and ligand-independent ErbB3 signaling. ErbB3 is a receptor that is typically expressed in many human cancers, and AV-203 has demonstrated preclinical activity in several different tumor models including breast, head and neck, lung, ovarian and pancreatic cancers. AV-203 can bind to human ERBB3 and inhibit binding of the ligand Neuregulin1 (NRG1) to ERBB3 to block the signal pathway which is associated with proliferation and metastasis of tumor cells.

Note: Detailed emerging therapies assessment will be provided in the final report.

Rare NRG1 Fusion Market Outlook

NRG1 Fusion is a rare but potentially actionable oncogenic driver that is present in some solid tumors. These fusions can promote pathologic signaling via MAPK and other canonical pathways. The most frequently reported NRG1 fusion is CD74-NRG1, which most commonly occurs in patients with invasive mucinous adenocarcinomas (IMAs) of the lung, although several other NRG1 fusion partners have been identified in patients with lung cancer, including ATP1B1, SDC4, and RBPMS. While there are studies of therapeutic efficacy with agents that target Erb-B2/Erb-B3, little is known about the characteristics of these fusions. Being a rare disorder, there is no specific treatment for NRG1 Fusion.


Currently, there are no approved targeted therapies for NRG1 fusions. Standard therapy for advanced tumors harboring NRG1 fusions remains chemotherapy and/or immunotherapy or novel anti–PD-1 or anti–PD-L1 agents. The problem with utilizing these therapies is that response tends to be suboptimal for patients with NRG1 fusions. The outcomes of preclinical studies have suggested that repurposing FDA-approved HER inhibitors, such as Afatinib (Gilotrif), maybe a highly attractive therapeutic strategy for NRG1 fusion-positive tumors.


At present, some companies have indulged themselves in initiating clinical trials that investigate new treatment options or studying how to use existing treatment options better. Key players such as Rain Therapeutics (Tarloxotinib), Elevation Oncology (Seribantumab), Merus (Zenocutuzumab), Eli Lilly and Company (Mirikizumab), AVEO Oncology (AV-203), Hummingbird Bioscience (HMBD-001, preclinical phase), and several others are investigating their candidates for the management of Rare NRG1 Fusions.


Key Findings

The Rare NRG1 Fusion market size in the 8MM is expected to change during the study period 2018–2030. The therapeutic market of Rare NRG1 Fusion in the eight major markets is expected to increase during the study period (2018–2030) with a CAGR of 19.0%. According to the estimates, the highest market size of NRG1 Fusion is found in the United States followed by China.


The United States Market Outlook

The total market size of NRG1 Fusion therapies in the United States is expected to increase with a CAGR of 20.1% in the study period (2018–2030).


EU-5 Countries: Market Outlook

The total market size of NRG1 Fusion therapies in EU-5 countries is expected to increase with a CAGR of 17.7% in the study period (2018–2030).


Japan Market Outlook

The total market size of NRG1 Fusion therapies in Japan is expected to increase with a CAGR of 17.3% in the study period (2018–2030).


China Market Outlook

The total market size of NRG1 Fusion therapies in China is expected to increase with a CAGR of 19.2% in the study period (2018–2030).

Rare NRG1 Fusion Pipeline Development Activities

The drugs which are in pipeline include:

1. Tarloxotinib (Rain Therapeutics)

2. MM-121/Seribantumab (Elevation Oncology)

3. Zenocutuzumab/MCLA-128 (Merus)

4. AV-203/CAN017 (CANbridge Pharmaceuticals/AVEO Oncology)

Note: Detailed emerging therapies assessment will be provided in the final report.

Analyst Commentary

  • According to the estimates, the highest market size in rare NRG1 Fusions will be contributed from the United States owing to the higher patient pool and higher treatment cost followed by China and Japan.
  • Due to the relative novelty of mutation and lack of extensive research and development, the pipeline of rare NRG1 fusions is still evolving and most of the drugs are still in the very early phase of development.
  • Among emerging therapies, Zenocutuzumab from Merus N.V. is expected to garner the highest patient share owing to novel MoA, visibility around the efficacy data from the ongoing trials, and also the early mover advantage.

KOL-Views

To keep up with current market trends, we take KOLs and SME’s opinion working in the Rare NRG1 Fusion domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Rare NRG1 Fusion market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Rare NRG1 Fusion Market by using various Competitive Intelligence tools that includes – SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Rare NRG1 Fusion, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies.
  • Comprehensive insight has been provided into the Rare NRG1 Fusion epidemiology and treatment in the 8MM.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Rare NRG1 Fusion is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the Rare NRG1 Fusion market; historical and forecasted is included in the report, covering drug outreach in the 8MM.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Rare NRG1 Fusion market.

Report Highlights

  • In the coming years, the Rare NRG1 Fusion market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Rare NRG1 Fusion R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Rare NRG1 Fusion. The launch of emerging therapies will significantly impact the Rare NRG1 Fusion market.
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Rare NRG1 Fusion.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Rare NRG1 Fusion Report Insights

  • Patient Population
  • Therapeutic Approaches
  • NRG1 Fusion Pipeline Analysis
  • NRG1 Fusion Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Rare NRG1 Fusion Report Key Strengths

  • 10 Years Forecast
  • 8MM Coverage
  • NRG1 Fusion Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Rare NRG1 Fusion Report Assessment

  • SWOT Analysis
  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Conjoint Analysis
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Rare NRG1 Fusion Market share (%) distribution in 2018 and how it would look like in 2030?
  • What would be the Rare NRG1 Fusion total market size as well as market size by therapies across the 8MM during the study period (2018–2030)?
  • What are the key findings of the market across the 8MM and which country will have the largest Rare NRG1 Fusion market size during the study period (2018–2030)?
  • At what CAGR, the Rare NRG1 Fusion market is expected to grow in the 8MM during the study period (2018–2030)?
  • What would be the Rare NRG1 Fusion market outlook across the 8MM during the study period (2018–2030)?
  • What would be the Rare NRG1 Fusion market growth till 2030 and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
  • Rare NRG1 Fusion patient types/pool where unmet need is more and whether emerging therapies will be able to address the residual unmet need?
  • How emerging therapies are performing on the parameters like efficacy, safety, route of administration (RoA), treatment duration, and frequencies based on their clinical trial results?
  • Among the emerging therapies, what are the potential therapies which are expected to disrupt the Rare NRG1 Fusion market?


Epidemiology Insights:

  • What are the disease risks, burdens, and unmet needs of the Rare NRG1 Fusion?
  • What is the historical Rare NRG1 Fusion patient pool in the eight major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, and China?
  • What would be the forecasted patient pool of Rare NRG1 Fusion in the 8 major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) Japan, and China?
  • What will be the growth opportunities in the 8MM concerning the patient population about Rare NRG1 Fusion?
  • Out of all the 8MM countries, which country would have the highest incident population of Rare NRG1 Fusion during the study period (2018–2030)?
  • At what CAGR the population is expected to grow in the 8MM during the study period (2018–2030)?
  • What are the various recent and upcoming events which are expected to improve the diagnosis of Rare NRG1 Fusion?

Current Treatment Scenario and Emerging Therapies:

  • What are the current options for the treatment of Rare NRG1 Fusion?
  • What are the current treatment guidelines for the treatment of Rare NRG1 Fusion in the US, Europe, Japan, and China?
  • How many companies are developing therapies for the treatment of Rare NRG1 Fusion?
  • How many therapies are developed by each company for the treatment of Rare NRG1 Fusion?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of Rare NRG1 Fusion?
  • What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Rare NRG1 Fusion therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Rare NRG1 Fusion and their status?
  • What are the key designations that have been granted for the emerging therapies for Rare NRG1 Fusion?
  • What is the global historical and forecasted market of Rare NRG1 Fusion?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Rare NRG1 Fusion market.
  • To understand the future market competition in the Rare NRG1 Fusion market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Rare NRG1 Fusion in the US, Europe (Germany, France, Italy, Spain, and the United Kingdom) Japan, and China.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the Rare NRG1 Fusion market.
  • To understand the future market competition in the Rare NRG1 Fusion market.

1. Key Insights

2. Report Introduction

3. Rare NRG1 Fusion Market Overview at a Glance

3.1. Market Share (%) Distribution of Rare NRG1 Fusion in 2018

3.2. Market Share (%) Distribution of Rare NRG1 Fusion in 2030

4. Executive Summary of Rare NRG1 Fusion

5. Epidemiology and Market Methodology

6. Disease Background and Overview

6.1. Introduction

6.2. Cancers related to Solid tumor

6.2.1. Brain Tumor

6.2.2. Bladder Cancer

6.2.3. Breast Cancer

6.2.4. Lung Cancer

6.2.5. Colorectal cancer

6.2.6. Pancreatic ductal adenocarcinoma

6.2.7. Prostate cancer

6.2.8. Ovarian cancer

6.2.9. Kidney cancer

6.2.10. Common Pediatric Solid Tumor Cancers

6.3. Mutations in Cancers related to Solid Tumor

6.3.1. KRAS Mutation

6.3.2. ALK Mutation

6.3.3. PIK3CA Mutation

6.3.4. BRAF Mutation

6.3.5. MET Mutation

6.3.6. ROS1 mutation

6.3.7. HER2 Mutation

6.3.8. EGFR Mutation

6.3.9. NRG1 fusion

6.4. Normal function of Neuregulin

6.4.1. Oncogenic mechanism of NRG1 fusion

6.4.2. NRG1 Fusions by tumor type

6.4.3. Fusion partners of neuregulins

6.5. Diagnosis

6.5.1. Next-Generation Sequencing (NGS)

6.5.2. Immunohistochemistry (IHC)

6.5.3. Fluorescence in situ hybridization (FISH)

6.5.4. Targeted RNA-sequencing (RNA-Seq)

6.5.5. Anchored Multiplex PCR (AMP)

6.6. Treatment and Management

6.6.1. Chemotherapy

6.6.2. Immunotherapy

6.6.3. Radiation Therapy

6.6.4. New Promising Agents

7. Epidemiology and Patient Population

7.1. Key Findings

7.2. Epidemiology of Rare NRG1 Fusion

7.3. Epidemiology Scenario: 8MM

7.3.1. Total Incident Cases of NRG1 Fusion

7.3.2. Total Stage-specific Cases of NRG1 Fusion

7.3.3. Total Treated Cases of NRG1 Fusion

8. The United States

8.1. Total Incident Cases of NRG1 Fusion

8.2. Total Stage-specific Cases of NRG1 Fusion

8.3. Total Treated Cases of NRG1 Fusion

9. EU-5

9.1. Germany

9.1.1. Total Incident Cases of NRG1 Fusion

9.1.2. Total Stage-specific Cases of NRG1 Fusion

9.1.3. Total Treated Cases of NRG1 Fusion

9.2. France

9.2.1. Total Incident Cases of NRG1 Fusion

9.2.2. Total Stage-specific Cases of NRG1 Fusion

9.2.3. Total Treated Cases of NRG1 Fusion

9.3. Italy

9.3.1. Total Incident Cases of NRG1 Fusion

9.3.2. Total Stage-specific Cases of NRG1 Fusion

9.3.3. Total Treated Cases of NRG1 Fusion

9.4. Spain

9.4.1. Total Incident Cases of NRG1 Fusion

9.4.2. Total Stage-specific Cases of NRG1 Fusion

9.4.3. Total Treated Cases of NRG1 Fusion

9.5. The United Kingdom

9.5.1. Total Incident Cases of NRG1 Fusion

9.5.2. Total Stage-specific Cases of NRG1 Fusion

9.5.3. Total Treated Cases of NRG1 Fusion

10. Japan

10.1. Total Incident Cases of NRG1 Fusion

10.2. Total Stage-specific Cases of NRG1 Fusion

10.3. Total Treated Cases of NRG1 Fusion

11. China

11.1. Total Incident Cases of NRG1 Fusion

11.2. Total Stage-specific Cases of NRG1 Fusion

11.3. Total Treated Cases of NRG1 Fusion

12. Patient Journey

13. Key Endpoints in NRG1 Fusion Clinical Trials

14. Emerging Therapies

14.1. Tarlox (Tarloxotinib Bromide): Rain Therapeutics

14.1.1. Product Description

14.1.2. Other Developmental Activities

14.1.3. Clinical Development

14.1.4. Safety and Efficacy

14.2. MM-121 (Seribantumab): Elevation Oncology

14.2.1. Product Description

14.2.2. Other Developmental Activities

14.2.3. Clinical Development

14.3. Zeno (MCLA-128; Zenocutuzumab): Merus

14.3.1. Product Description

14.3.2. Other Developmental Activities

14.3.3. Clinical Development

14.3.4. Safety and Efficacy

14.4. AV-203 (CAN017; ERBB3 MAb): AVEO Oncology and CANbridge Pharmaceuticals

14.4.1. Product Description

14.4.2. Other Developmental Activities

14.4.3. Clinical Development

14.4.4. Safety and Efficacy

15. Rare NRG1 Fusion: 8 Major Market Analysis

15.1. Key Findings

15.2. Market Outlook

15.3. 8MM Market Size

15.3.1. Total Market Size of NRG1 Fusion in the 8MM

15.3.2. Market Size of NRG1 Fusion by Therapies in the 8MM

16. The United States Market Size

16.1. Total Market Size of NRG1 Fusion in the United States

16.2. Market Size of NRG1 Fusion by Therapies in the United States

17. EU-5 Market Size

17.1. Germany

17.1.1. Total Market size of NRG1 Fusion in Germany

17.1.2. Market Size of NRG1 Fusion by Therapies in Germany

17.2. France

17.2.1. Total Market size of NRG1 Fusion in France

17.2.2. Market Size of NRG1 Fusion by Therapies in France

17.3. Italy

17.3.1. Total Market size of NRG1 Fusion in Italy

17.3.2. Market Size of NRG1 Fusion by Therapies in Italy

17.4. Spain

17.4.1. Total Market size of NRG1 Fusion in Spain

17.4.2. Market Size of NRG1 Fusion by Therapies in Spain

17.5. The United Kingdom

17.5.1. Total Market size of NRG1 Fusion in the United Kingdom

17.5.2. Market Size of NRG1 Fusion by Therapies in the United Kingdom

18. Japan

18.1. Total Market size of NRG1 Fusion in Japan

18.2. Market Size of NRG1 Fusion by Therapies in Japan

19. China

19.1. Total Market size of NRG1 Fusion in China

19.2. Market Size of NRG1 Fusion by Therapies in China

20. Market Drivers

21. Market Barriers

22. SWOT Analysis

23. Unmet Needs

24. Appendix

24.1. Bibliography

24.2. Report Methodology

25. DelveInsight Capabilities

26. Disclaimer

27. About DelveInsight

List of Table

Table 1: Summary of Rare NRG1 Fusion, Market, Epidemiology, and Key Events (2018–2030)

Table 2: Genomic Testing Method

Table 3: The advantages and disadvantages of different assays available for the detection of NRG1

Table 4: ErbB-targeted treatment in patients with NRG1 fusion-positive tumors

Table 5: Total Incident Cases of NRG1 Fusion in the 8MM (2018–2030)

Table 6: Total Stage-specific Cases of NRG1 Fusion in the 8MM (2018–2030)

Table 7: Total Treated Cases of NRG1 Fusion in the 8MM (2018–2030)

Table 8: Total Incident Cases of NRG1 Fusion in the United States (2018–2030)

Table 9: Total Stage-specific Cases of NRG1 Fusion in the United States (2018–2030)

Table 10: Total Treated Cases of NRG1 Fusion in the United States (2018–2030)

Table 11: Total Incident Cases of NRG1 Fusion in Germany (2018–2030)

Table 12: Total Stage-specific Cases of NRG1 Fusion in Germany (2018–2030)

Table 13: Total Treated Cases of NRG1 Fusion in Germany (2018–2030)

Table 14: Total Incident Cases of NRG1 Fusion in France (2018–2030)

Table 15: Total Stage-specific Cases of NRG1 Fusion in France (2018–2030)

Table 16: Total Treated Cases of NRG1 Fusion in France (2018–2030)

Table 17: Total Incident Cases of NRG1 Fusion in Italy (2018–2030)

Table 18: Total Stage-specific Cases of NRG1 Fusion in Italy (2018–2030)

Table 19: Total Treated Cases of NRG1 Fusion in Italy (2018–2030)

Table 20: Total Incident Cases of NRG1 Fusion in Spain (2018–2030)

Table 21: Total Stage-specific Cases of NRG1 Fusion in Spain (2018–2030)

Table 22: Total Treated Cases of NRG1 Fusion in Spain (2018–2030)

Table 23: Total Incident Cases of NRG1 Fusion in the United Kingdom (2018–2030)

Table 24: Total Stage-specific Cases of NRG1 Fusion in the United Kingdom (2018–2030)

Table 25: Total Treated Cases of NRG1 Fusion in the United Kingdom (2018–2030)

Table 26: Total Incident Cases of NRG1 Fusion in Japan (2018–2030)

Table 27: Total Stage-specific Cases of NRG1 Fusion in Japan (2018–2030)

Table 28: Total Treated Cases of NRG1 Fusion in Japan (2018–2030)

Table 29: Total Incident Cases of NRG1 Fusion in China (2018–2030)

Table 30: Total Stage-specific Cases of NRG1 Fusion in China (2018–2030)

Table 31: Total Treated Cases of NRG1 Fusion in China (2018–2030)

Table 32: Tarlox (Tarloxotinib Bromide), Clinical Trial Description, 2021

Table 33: MM-121 (Seribantumab), Clinical Trial Description, 2021

Table 34: Zeno (MCLA-128; Zenocutuzumab), Clinical Trial Description, 2021

Table 35: AV-203 (ERBB3 MAb), Clinical Trial Description, 2021

Table 36: 8MM Market Size of NRG1 Fusion in USD Million (2018–2030)

Table 37: 8MM Market Size of NRG1 Fusion by Therapies in USD Million (2018–2030)

Table 38: The United States Market Size of NRG1 Fusion in USD Million (2018–2030)

Table 39: The United States Market Size of NRG1 Fusion by Therapies in USD Million (2018–2030)

Table 40: Germany Market Size of NRG1 Fusion in USD Million (2018–2030)

Table 41: Germany Market Size of NRG1 Fusion by Therapies in USD Million (2018–2030)

Table 42: France Market Size of NRG1 Fusion in USD Million (2018–2030)

Table 43: France Market Size of NRG1 Fusion by Therapies in USD Million (2018–2030)

Table 44: Italy Market Size of NRG1 Fusion in USD Million (2018–2030)

Table 45: Italy Market Size of NRG1 Fusion by Therapies in USD Million (2018–2030)

Table 46: Spain Market Size of NRG1 Fusion in USD Million (2018–2030)

Table 47: Spain Market Size of NRG1 Fusion by Therapies in USD Million (2018–2030)

Table 48: The United Kingdom Market Size of NRG1 Fusion in USD Million (2018–2030)

Table 49: The United Kingdom Market Size of NRG1 Fusion by Therapies in USD Million (2018–2030)

Table 50: Japan Market Size of NRG1 Fusion in USD Million (2018–2030)

Table 51: Japan Market Size of NRG1 Fusion by Therapies in USD Million (2018–2030)

Table 52: China Market Size of NRG1 Fusion in USD Million (2018–2030)

Table 53: China Market Size of NRG1 Fusion by Therapies in USD Million (2018–2030)

List of Figures

Figure 1: Epidemiology and Market Methodology

Figure 2: Various types of Solid tumors

Figure 3: Osteosarcoma

Figure 4: KRAS GTPase Cycle

Figure 5: ALK Gene Arrangements

Figure 6: PI3K Signaling Cascade

Figure 7: MAP Kinase Pathway

Figure 8: HGF/MET Pathway

Figure 9: Mechanism of action of NRG1

Figure 10: Oncogenic mechanisms of NRG1 fusions

Figure 11: NRG1 Fusion by Tumor type

Figure 12: NRG1 Fusion Partners

Figure 13: CD74-NRG1 Fusion pathway

Figure 14: CD74-NRG1 Fusion pathway

Figure 15: Novel treatment options for NRG1 Fusion

Figure 16: Global Heat Map of All Cancers

Figure 17: Total Incident Cases of NRG1 Fusion in the 8MM (2018–2030)

Figure 18: Total Metastatic (including locally advanced) Stage-specific Cases of NRG1 Fusion in the 8MM (2018–2030)

Figure 19: Total Treated Cases of NRG1 Fusion in the 8MM (2018–2030)

Figure 20: Total Incident Cases of NRG1 Fusion in the United States (2018–2030)

Figure 21: Total Metastatic (including locally advanced) Stage-specific Cases of NRG1 Fusion in the United States (2018–2030)

Figure 22: Total Treated Cases of NRG1 Fusion in the United States (2018–2030)

Figure 23: Total Incident Cases of NRG1 Fusion in Germany (2018–2030)

Figure 24: Total Metastatic (including locally advanced) Stage-specific Cases of NRG1 Fusion in Germany (2018–2030)

Figure 25: Total Treated Cases of NRG1 Fusion in Germany (2018–2030)

Figure 26: Total Incident Cases of NRG1 Fusion in France (2018–2030)

Figure 27: Total Metastatic (including locally advanced) Stage-specific Cases of NRG1 Fusion in France (2018–2030)

Figure 28: Total Treated Cases of NRG1 Fusion in France (2018–2030)

Figure 29: Total Incident Cases of NRG1 Fusion in Italy (2018–2030)

Figure 30: Total Metastatic (including locally advanced) Stage-specific Cases of NRG1 Fusion in Italy (2018–2030)

Figure 31: Total Treated Cases of NRG1 Fusion in Italy (2018–2030)

Figure 32: Total Incident Cases of NRG1 Fusion in Spain (2018–2030)

Figure 33: Total Metastatic (including locally advanced) Stage-specific Cases of NRG1 Fusion in Spain (2018–2030)

Figure 34: Total Treated Cases of NRG1 Fusion in Spain (2018–2030)

Figure 35: Total Incident Cases of NRG1 Fusion in the United Kingdom (2018–2030)

Figure 36: Total Metastatic (including locally advanced) Stage-specific Cases of NRG1 Fusion in the United Kingdom (2018–2030)

Figure 37: Total Treated Cases of NRG1 Fusion in the United Kingdom (2018–2030)

Figure 38: Total Incident Cases of NRG1 Fusion in Japan (2018–2030)

Figure 39: Total Metastatic (including locally advanced) Stage-specific Cases of NRG1 Fusion in Japan (2018–2030)

Figure 40: Total Treated Cases of NRG1 Fusion in Japan (2018–2030)

Figure 41: Total Incident Cases of NRG1 Fusion in China (2018–2030)

Figure 42: Total Metastatic (including locally advanced) Stage-specific Cases of NRG1 Fusion in China (2018–2030)

Figure 43: Total Treated Cases of NRG1 Fusion in China (2018–2030)

Figure 44: Seribantumab Mechanism

Figure 45: MCLA-128 Mechanism

Figure 46: Market Size of NRG1 Fusion in the 8MM, USD Million (2018–2030)

Figure 47: 8MM Market Size of NRG1 Fusion by Therapies in USD Million (2018–2030)

Figure 48: Market Size of NRG1 Fusion in the United States, USD Million (2018–2030)

Figure 49: The United States Market Size of NRG1 Fusion by Therapies in USD Million (2018–2030)

Figure 50: Market Size of NRG1 Fusion in Germany, USD Million (2018–2030)

Figure 51: Germany Market Size of NRG1 Fusion by Therapies in USD Million (2018–2030)

Figure 52: Market Size of NRG1 Fusion in France, USD Million (2018–2030)

Figure 53: France Market Size of NRG1 Fusion by Therapies in USD Million (2018–2030)

Figure 54: Market Size of NRG1 Fusion in Italy, USD Million (2018–2030)

Figure 55: Italy Market Size of NRG1 Fusion by Therapies in USD Million (2018–2030)

Figure 56: Market Size of NRG1 Fusion in Spain, USD Million (2018–2030)

Figure 57: Spain Market Size of NRG1 Fusion by Therapies in USD Million (2018–2030)

Figure 58: Market Size of NRG1 Fusion in the United Kingdom, USD Million (2018–2030)

Figure 59: The United Kingdom Market Size of NRG1 Fusion by Therapies in USD Million (2018–2030)

Figure 60: Market Size of NRG1 Fusion in Japan, USD Million (2018–2030)

Figure 61: Japan Market Size of NRG1 Fusion by Therapies in USD Million (2018–2030)

Figure 62: Market Size of NRG1 Fusion in China, USD Million (2018–2030)

Figure 63: China Market Size of NRG1 Fusion by Therapies in USD Million (2018–2030)

  • Rain Therapeutics
  • Elevation Oncology
  • Merus
  • CANbridge Pharmaceuticals
  • AVEO Oncology
  • Tags:
  • Rare NRG1 Fusion market
  • Rare NRG1 Fusion market research
  • Rare NRG1 Fusion market insight
  • Rare NRG1 Fusion market trends
  • Rare NRG1 Fusion market forecast
  • Rare NRG1 Fusion market share
  • Rare NRG1 Fusion pipeline drugs
  • Rare NRG1 Fusion treatment algorith...
  • Rare NRG1 Fusion drugs
  • Rare NRG1 Fusion sales forecasting
  • Rare NRG1 Fusion market size
  • Rare NRG1 Fusion disease
  • Rare NRG1 Fusion epidemiology
  • Rare NRG1 Fusion

Forward to Friend

Need A Quote